Eli Lilly and Company
5-methyl-1,3,4-oxadiazol-2-yl compounds
Last updated:
Abstract:
The present invention provides a compound of Formula I: ##STR00001## or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treatment of neurodegenerative diseases and disorders, such as Alzheimer's disease.
Status:
Grant
Type:
Utility
Filling date:
18 May 2018
Issue date:
13 Aug 2019